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vs. OR = 0.47, p < 0.05). Compliance between males and females
remained similar in both periods (p > 0.05). CONCLUSION:
Despite signiﬁcant improvement in recent years, the proportion
of post-MI patients in UK, particularly the elderly, receiving
aspirin-statin combination is signiﬁcantly less than the NSF
treatment goals. Intensive dissemination efforts are required to
achieve greater impact of this policy.
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OBJECTIVE: It is known that initiation of drug therapy for
hypercholesterolaemia once diagnosed, is improving and now
stands at around 60%. What is unclear is whether there is a delay
between patients being identiﬁed with elevated cholesterol and a
subsequent diagnosis of hypercholesterolaemia. To address this
uncertainty, this database study followed patients with an initial
recording of cholesterol greater than 5mmol/L, through diagno-
sis and advice to treatment. METHODS: The DIN-LINK data-
base, containing anonymised medical records from 1.5 million
patients collected via GP practice computers, was used to iden-
tify and follow-up a cohort of patients with a recorded choles-
terol level greater than 5mmol/L. For inclusion, each patient had
to have a baseline measurement taken between April 2001 and
April 2002, a minimum of 12 months follow-up data and not
been diagnosed with hypercholesterolaemia or be prescribed
cholesterol lowering medications prior to the cholesterol mea-
surement. RESULTS: A total of 3418 patients were identiﬁed as
meeting the criteria. Of these, 991 (29%) were diagnosed as
hypercholesterolaemic within 12 months, three-quarters of these
on the same date as the recording of the elevated cholesterol. Of
the initially identiﬁed 3418 patients, only 257 (8%) were pre-
scribed cholesterol lowering medication within 12 months of the
initial reading. CONCLUSIONS: For patients who are known
to have elevated cholesterol 71% fail to receive a diagnosis of
hypercholesterolaemia and 92% do not receive medication
within 12 months of initial reading. Further analyses are required
to determine the impact of these delays in diagnosis on patient
outcomes.
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OBJECTIVE: It is known that initiation of drug therapy for
hypertension, once diagnosed, is now relatively high at around
85%. What is unclear is whether there is a delay between
patients being identiﬁed with elevated blood pressure and a sub-
sequent diagnosis of hypertension. To address this uncertainty,
this database study followed patients with an initial recording of
systolic blood pressure greater than 150mmHg, through diag-
nosis and advice to treatment. METHODS: The DIN-LINK
database, containing anonymised medical records from 1.5
million patients collected via GP practice computers, was used
to identify and follow-up a cohort of patients with a recorded
systolic blood pressure greater than 150mmHg. For inclusion
each patient had to have a baseline measurement taken between
April 2001 and April 2002, a minimum of 12 months follow-up
data and not been diagnosed with hypertension or be prescribed
antihypertensive medications prior to the blood pressure 
measurement. RESULTS: A total of 2880 patients were identi-
ﬁed as meeting the criteria. Of these, 1469 (51%) were diagnosed
as hypertensive within 12 months, two-thirds of these within one
month of the recording of elevated blood pressure. Of the 
initially identiﬁed 2880 patients, only 579 (20%) were pre-
scribed blood pressure lowering medication within 12 months of
the initial reading. CONCLUSIONS: For patients who are
known to have an elevated blood pressure 49% fail to receive a
diagnosis of hypertension and 80% do not receive medication
within 12 months of initial reading. Further analyses are required
to determine the impact of these delays in diagnosis on patient
outcomes.
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OBJECTIVES: To evaluate associations between insurance cov-
erage and length of stay, death, and discharge destination of
patients hospitalized for non-hemorrhagic stroke. METHODS:
A retrospective analysis was conducted of patients hospitalized
for <30 days with a primary diagnosis of nonhemorrhagic stroke
(ICD-9 code = 436) identiﬁed from a 10% sub-sample (745,099
cases) of the Health care Cost and Utilization Project (HCUP)
2000 database. The database contains hospitalizations from hos-
pitals in 28 U.S. states. Associations between insurance coverage
(Medicare, Medicaid or private/HMO) and length of stay, in-
hospital death, and discharge destinations were analyzed using
ANOVA, logistic and multinomial regression respectively, con-
trolling for age, gender, race, admission type, admission source,
comorbidities and socioeconomic status. Statistical analyses of
the data were performed using SAS for Windows Version 8.2.
An alpha of <0.05 was required for signiﬁcance. RESULTS:
Insurance type was not statistically signiﬁcant in predicting LOS
after adjusting for other risk factors (p = 0.2095). The interac-
tions between insurance coverage and age, and between insur-
ance and admission source were signiﬁcant. After controlling for
risk factors, insurance type had a signiﬁcant association with in-
hospital death rate (p = 0.0335). Medicare cases were signiﬁ-
cantly more likely to be discharged to home-health care (p =
0.0006), while private/HMO cases were less likely to be dis-
charged to home-health care (p = 0.0071), even after controlling
for risk factors. CONCLUSIONS: Insurance coverage had a 
signiﬁcant association with in-hospital death risk and discharge
destination in patients hospitalized for non-hemorrhagic 
stroke. Further study is needed to elucidate the basis for these
associations.
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OBJECTIVE: The objective of this study was to determine
whether use of a drug-eluting stent (DES) affected the likelihood
of receiving a glycoprotein (GP) IIb/IIIa inhibitor among patients
undergoing percutaneous coronary intervention (PCI) with a
stent. GP IIb/IIIa inhibitors have been used in conjunction with
PCI to reduce ischemic events at or just following the time of the
procedure. Drug-eluting stents, approved by the FDA on April
23, 2003, have been reported to decrease restenosis of a vessel
over the long-term. GPIIa/IIIa inhibitors and drug-eluting stents
